AstraZeneca Announced Tezspire Approved For Self-administration In The EU In A New Pre-filled Pen
AstraZeneca's Tezspire (tezepelumab) has received a positive opinion from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.